Table 1.

Eligibility criteria for the systematic literature review

Description	Inclusion criteria	Exclusion criteria
Population	Any patients receiving treatment in a hospital settinga	Patients treated exclusively at home
Intervention/comparator	Studies comparing any IV- versus SC-administered interventions	Studies not comparing IV- versus SC-administered interventions
Outcomes	Costs and time/resource use  Direct medical costs:   Port versus PICC versus CVC costs  Direct non-medical costs:   Transportation   Childcare costs   Additional caregiver costs  Indirect/societal costs:   Productivity losses   Absenteeism   Presenteeism   Withdrawal from labor force  Estimates of time/resource use including:   Hospitalization and length of stay   Pharmacist time   Nurse time   Drug wastage  Cost drivers  Time-and-motion outcomes including:   Patient waiting time   Drug preparation time   Administration time   Monitoring/observation time   Nurse set-up time   AE management time	Clinical outcomes
Study design/setting	Cost and time/resource use studies: Any studies reporting original cost and/or time/resource use data	Systematic literature reviewsb Studies based on animal models Preclinical and biologic studies Narrative reviews, editorials, opinions
Language of publication	Not restricted	NA
Date of publication	Full publications: 2012c to present Conference abstracts: 2017 to presentd	Full publications prior to 2012 Conference abstracts prior to 2017
Countries	Not restricted	NA

AE adverse event, CVC central venous catheter, IV intravenous, NA not applicable, PICC peripherally inserted central catheter, SC subcutaneous, SLR systematic literature review

^aAs a result of the deliberately inclusive eligibility criteria originally designed for this SLR, a larger than anticipated number of potentially eligible studies were identified after the completion of first pass screening. A decision was taken to deprioritize any study that did not focus on a population of patients with a cancer diagnosis

^bRelevant systematic literature reviews were reference checked before being excluded

^cYear of approval of SC trastuzumab

^dConference abstracts that were superseded by a full publication were excluded unless the abstract reported some unique data